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Background: To evaluate the efficacy of rifaximin for reduction of gastrointestinal symptoms 
in patients with irritable bowel syndrome (IBS).
Methods: Medical records were identified for consecutive patients diagnosed with IBS 
  according to Rome III criteria, who had abnormal lactulose breath test results and had received 
rifaximin 1200 mg/day for 10 days. The efficacy of rifaximin for reducing gastrointestinal 
symptoms and for eradicating small intestinal bacterial overgrowth was ascertained in these 
patients. In addition, these endpoints were examined in patients who were initially unresponsive 
to rifaximin 1200 mg/day and received subsequent rifaximin 2400 mg/day.
Results: Patients who received rifaximin 1200 mg/day (n = 162) experienced a mean improve-
ment of 52% in global IBS symptoms at the end of rifaximin treatment. Similarly, initially 
unresponsive patients who received additional rifaximin 2400 mg/day (n = 81) experienced a 
53% mean improvement in global IBS symptoms. Forty-nine percent of patients who received 
initial rifaximin and 47% of patients who received high-dose rifaximin achieved $50% global 
symptom improvement during at least one follow-up visit. Normalization of lactulose breath 
test results was only apparent in some patients who received high-dose rifaximin. Rifaximin 
was well tolerated.
Conclusion: Rifaximin 1200 mg/day for 10 days reduced gastrointestinal symptoms in patients 
with IBS. Patients with incomplete symptom resolution may respond to increased doses of 
rifaximin.
Keywords: small intestinal bacterial overgrowth, irritable bowel syndrome, rifaximin, lactulose 
breath test
Introduction
Irritable bowel syndrome (IBS) is a disease of altered gastrointestinal motility, in 
which patients often experience predominant symptoms of constipation or diarrhea.1 
It is prevalent in the US, affecting up to 20% of individuals,2 but the etiology of the 
disease remains elusive.3 Several psychological and organic causes have been postulated 
to contribute to the development of IBS, including psychosocial factors   (depression, 
anxiety),3,4 alterations in gastrointestinal neurotransmission (serotonin levels),3,4 and 
small intestinal bacterial overgrowth.3–6 Small intestinal bacterial overgrowth, in particu-
lar, has come into the spotlight because of data suggesting that patients with IBS may 
have altered intestinal microflora, with decreased concentrations of coliforms, lactoba-
cilli, and bifidobacteria, as well as increased numbers of anaerobes, Escherichia coli, 
and bacteroides.3,7,8 These recent advances in   understanding the   etiology of IBS have 
provided a new avenue for potential therapies, such as   nonsystemic antibiotics, that 
may target disease pathology.9–12Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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Typical treatments for IBS, such as antispasmodics, 
antidepressants, C-2 chloride channel activators, and 5-HT3 
receptor antagonists, focus on symptom relief,1,13 and do not 
address the underlying cause of the disorder. Current guide-
lines from the American College of Gastroenterology provide 
a strong recommendation (ie, 1B) for antidepressants, C-2 
chloride channel activators for females with constipation-
predominant IBS, and 5-HT3 receptor antagonists for females 
with severe diarrhea-predominant IBS. However, limited 
availability, tolerability, and efficacy for all IBS subtypes 
emphasize the necessity for other treatment options.14 The 
American College of Gastroenterology guidelines have 
strongly recommended the use of nonsystemic antibiotics, 
such as rifaximin, for IBS based on moderate evidence. 
Rifaximin is approved for treatment of travelers’ diarrhea and 
the reduction of hepatic encephalopathy recurrence, and has 
been shown to alleviate symptoms in patients with IBS.11,15–19 
Increased dosage of rifaximin has been shown to normalize 
glucose breath test results in patients with small intestinal 
bacterial overgrowth,20 and given the connection between 
small intestinal bacterial overgrowth and IBS, treatment with 
a higher dose of rifaximin may provide symptom relief in 
patients with recurrent IBS.
This retrospective chart review examined the efficacy 
of rifaximin 1200 mg/day in alleviating global symptoms 
in patients with IBS and the ability of high-dose rifaximin 
(2400 mg/day) to improve IBS symptoms in patients   initially 
unresponsive to rifaximin. The study also evaluated the 
ability of rifaximin to eradicate small intestinal bacterial 
overgrowth in patients with IBS.
Materials and methods
Patient population
Medical records from a single center were identified for 
consecutive patients diagnosed with IBS according to Rome 
III criteria, who were aged $16 years, had an abnormal 
lactulose breath test result between October 2006 and July 
2007, and had received rifaximin 1200 mg/day (Xifaxan®, 
Salix Pharmaceuticals, Inc, Morrisville, NC) for 10 days at 
any time. Before the lactulose breath test, patients were given 
dietary restrictions (eg, no beans or heavy meat 24 hours 
before testing), could not chew gum or participate in strenu-
ous physical exercise nine hours before testing, and were not 
allowed to smoke two hours before the lactulose breath test. 
For this test, patients ingested 10 g of lactulose. An abnormal 
lactulose breath test result was defined as a $10 ppm increase 
in baseline H2 or CH4 excretion within 90 minutes. Patients 
were excluded if they had used an oral antibiotic within three 
weeks before rifaximin treatment or if they had a history of 
inflammatory bowel disease, bowel resection surgery, or a 
colonic mucosal biopsy compatible with inflammatory bowel 
disease or microscopic colitis. Furthermore, patients were 
excluded if they displayed any of the following at baseline: 
a positive sprue screen (antigliadin antibody IgA, tissue trans-
glutaminase IgA, total IgA), a positive stool antigen test for 
Giardia or Cryptosporidium, positivity for fecal leukocytes, 
positivity for Clostridium difficile toxins A or B, or levels of 
C-reactive protein .8 mg/L.
Data extraction
Data for baseline IBS symptoms, rifaximin dosing   regimen, 
concomitant medication usage, and IBS symptom improve-
ment were extracted from patient charts. Only charts of 
patients who received initial treatment with rifaximin 
1200 mg/day and were retreated with rifaximin 2400 mg/day 
if symptoms continued were included in the analyses. 
  Collection of lactulose breath test results obtained initially 
and 4–14 days following rifaximin completion was also 
performed. Note was made of hydrogen-positive, methane-
positive, hydrogen- and methane-positive, flatline, negative, 
distal-positive, high-baseline, and inconclusive lactulose 
breath test results.
Response to initial rifaximin (1200 mg/day) and high-
dose rifaximin (2400 mg/day) was based on global symp-
tom improvement from baseline and was assessed by the 
patients using a visualized scale ranging from 0% to 100%. 
Patients were also asked to rate the percentage improve-
ment from baseline of specific IBS symptoms (abdominal 
pain or discomfort, bloating, constipation, diarrhea, gas, or 
other symptoms) at follow-up visits after both treatment 
  regimens. Symptom improvement was categorized as com-
plete improvement ($91%), partial improvement (1%–90%), 
or no improvement (0%). Diagnosis of IBS was noted to 
be constipation-predominant IBS, diarrhea-predominant 
IBS, or mixed-symptom IBS when reported. Completion 
of rifaximin therapy was ascertained from all charts, and 
when withdrawal from the study was noted, the reason was 
recorded as adverse event related or not related to rifaximin. 
Specific treatment-related adverse events were also collected 
from all charts.
Data analysis
The average percent global improvement of baseline IBS 
symptoms at the end of rifaximin therapy (both initial 
  rifaximin 1200 mg/day and retreatment with rifaximin 
2400 mg/day) was analyzed without regard to lactulose breath Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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test measurements. Percentages of patients with   improvement 
in global and IBS-related symptoms (eg, abdominal pain 
and discomfort, bloating, constipation, diarrhea, and gas) 
were recorded for each patient at all visits. The percent-
age of patients who achieved $50% global IBS symptom 
improvement during at least one follow-up visit ($50% best 
global improvement) was also ascertained. Normalization of 
lactulose breath test results within 4–14 days after rifaximin 
cessation and the percentage of patients with normal lactu-
lose breath test results and global symptom improvement at 
the end of rifaximin therapy were evaluated. Subanalyses 
were also conducted for improvement of global and specific 
IBS symptoms and lactulose breath test results by IBS sub-
classification (ie, diarrhea-predominant IBS, constipation-
predominant IBS, or mixed-symptom IBS).
Results
Patient population
A total of 236 patient charts were reviewed, and 162 were 
selected for further analysis after application of inclusion/
exclusion parameters. All 162 patients received initial treat-
ment with rifaximin 1200 mg/day for 10 days. Among these 
individuals, 45 (28%) were classified as having diarrhea-
predominant IBS, 33 (20%) were classified as having 
constipation-predominant IBS, and 24 (15%) were classified 
as having mixed-symptom IBS. Lactulose breath test results 
indicated that 91 patients (56%) were hydrogen positive, 
32 (20%) were methane positive, and 9 (6%) were positive 
for both hydrogen and methane (Table 1). In addition, 81 of 
the initial 162 patients (50%) received subsequent treatment 
with rifaximin 2400 mg/day for 10 days because of incom-
plete symptom resolution (Table 1).
response to initial treatment  
with rifaximin
Patients who received rifaximin 1200 mg/day experienced 
a mean improvement of 52% in global IBS symptoms at 
the end of rifaximin treatment (Figure 1). In addition, after 
initial rifaximin 1200 mg/day for 10 days, 49% of patients 
(79 of 162) reported $50% best global improvement in IBS 
symptoms (Figure 2). This improvement was IBS-subtype 
specific, with 56% of patients (25 of 45) diagnosed with 
diarrhea-predominant IBS experiencing $50% best global 
improvement compared with 45% of individuals (15 of 33) 
with constipation-predominant IBS (Figure 3). Complete 
symptom relief ($91% improvement) was achieved in 
19 of 162 patients (12%) and was not dependent on IBS 
subcategory (Table 2). Eight percent of patients (13 of 162) 
Table 1 Patient demographics and characteristics
Parameter Rifaximin 
1200 mg/day  
(n = 162)
Rifaximin 
2400 mg/day   
(n = 81)
Mean age (range), years 58 (17–91) 60 (17–91)
Male:Female  37:125 22:59
race, n (%) 43 (27) 25 (31)
  White 2 (1) 1 (1)
  Black 2 (1) 0 (0)
  Asian 4 (2) 2 (2)
  hispanic 2 (1) 2 (2)
  Other 109 (67) 51 (63)
  not reported 43 (27) 25 (31)
Mean duration of iBs  
(range), mo
113.1 (6–480) 128.4 (6–480)
Disease subclass, n (%)
  iBs-D 45 (28) 24 (30)
  iBs-C 33 (20) 16 (20)
  iBs-M 24 (15) 11 (14)
  not reported 60 (37) 30 (37)
Lactulose breath test results, n (%)a
  Distal positiveb 17 (10) 10 (12)
  hydrogen 91 (56) 44 (54)
  Methane 32 (20) 18 (22)
  hydrogen and methane 9 (6) 4 (5)
  high baselinec 23 (14) 10 (12)
  Flatlined 27 (17) 15 (19)
  negativee 4 (2) 1 (1)
  inconclusive 34 (21) 18 (22)
Notes: aPatients positive for hydrogen, methane, or both gases may have exhibited 
a high baseline or lacked a biphasic excretion pattern (distal positive); bpatients who 
did not exhibit a biphasic pattern of gas excretion; cpatients with $20 ppm before 
lactulose ingestion; dpatients with a ,10 ppm increase in gas excretion within 120 
minutes of lactulose ingestion; epatients with a ,10 ppm increase in gas excretion 
within 90 minutes of lactulose ingestion. 
Abbreviations:  iBs,  irritable  bowel  syndrome;  iBs-D,  diarrhea-predominant 
irritable  bowel  syndrome;  iBs-C,  constipation-predominant  irritable  bowel 
syndrome; iBs-M, mixed-symptom irritable bowel syndrome.
achieved   partial relief (1%–90%) of overall symptoms, with 
individuals having constipation-predominant IBS receiving 
the greatest benefit. The predominant symptom (diarrhea or 
constipation) was completely relieved in 13% of patients 
with diarrhea-predominant IBS and in 12% of patients with 
constipation-predominant IBS (Table 2). Similarly, 17% 
of patients with mixed-symptom IBS displayed complete 
relief of diarrhea, and 13% had complete relief of consti-
pation (Table 2). Only 2% of patients treated with initial 
rifaximin displayed a normal lactulose breath test result 
post-treatment.
response to further treatment  
with high-dose rifaximin
Patients who did not respond to initial rifaximin were admin-
istered additional rifaximin (2400 mg/day for 10 days, n = 81). 
Patients who received high-dose rifaximin (2400 mg/day) Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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Figure 2 Percentage of patients obtaining $50% best global improvement following 
rifaximin treatment. Global symptoms improved in 79 of 162 patients (49%) who 
received rifaximin 1200 mg/day for 10 days compared with 38 of 81 patients (47%) 
who received high-dose rifaximin (2400 mg/day) for 10 days. 
Note: aincludes patients who received additional high-dose rifaximin therapy.
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Rifaximin 1200 mg/da
(IBS-D, n = 45; IBS-C, n = 33)
Rifaximin 2400 mg/d
(IBS-D, n = 24; IBS-C, n = 16)
Figure 3 Percentage of patients with iBs-D or iBs-C who obtained $50% best 
global  improvement  following  rifaximin  treatment.  rifaximin  effectively  reduced 
irritable bowel syndrome symptoms in patients with either subtype. interestingly, 
rifaximin 2400 mg/day elicited $50% symptom improvement in patients with either 
subtype who initially lacked response to rifaximin 1200 mg/day.
Note:  aincludes  patients  who  received  additional  high-dose  rifaximin  therapy. 
Abbreviations:  iBs-C,  constipation-predominant  irritable  bowel  syndrome; 
iBs-D, diarrhea-predominant irritable bowel syndrome.
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Figure 1 Mean percent improvement in global iBs symptoms at the end of rifaximin 
treatment. The mean percent improvement in global iBs symptoms was similar in 
patients with iBs who received rifaximin 1200 mg/day for 10 days (52%) and in 
patients with iBs who received subsequent high-dose rifaximin (2400 mg/day) for 
10 days (53%). 
Note: aincludes patients who received additional high-dose rifaximin therapy.
Abbreviation: iBs, irritable bowel syndrome.
experienced a mean improvement in global IBS symptoms of 
53% at the termination of rifaximin therapy, which was similar 
to the percent improvement experienced in patients responsive 
to rifaximin 1200 mg/day (Figure 1). In addition, treatment 
with high-dose rifaximin elicited $50% best global symp-
tom improvement in patients initially lacking a response to 
lower-dose rifaximin. Among the 81 patients receiving further 
rifaximin treatment, 38 (47%) exhibited $50% best improve-
ment in overall global symptoms, which was similar to that 
reported during initial rifaximin 1200 mg/day for 10 days 
(Figure 2). Patients with mixed-symptom IBS received 
the greatest benefit from high-dose rifaximin, with six of 
11 patients (55%) reporting best global improvement $50%. 
More patients with diarrhea-predominant IBS experienced 
best global improvement $50% compared with individuals 
with constipation-predominant IBS, with 13 of 24 patients 
with diarrhea-predominant IBS (54%) displaying best global 
improvement $50% compared with only six of 16 patients 
with constipation-predominant IBS (38%,   Figure 3). Com-
plete symptom reduction ($91%) was reported in nine of 81 
patients (11%) and was not subtype dependent. However, com-
plete reduction of the predominant symptom (diarrhea or con-
stipation) was greater in patients with diarrhea-predominant 
IBS (17%) than in patients experiencing constipation-
predominant IBS (6%, Table 2). Interestingly, patients with 
mixed-symptom IBS reported larger remission of diarrheal 
symptoms (18%) than constipation symptoms (0%, Table 2). 
Partial relief (1%–90%) of global IBS symptoms was achieved 
in 10% of initially unresponsive patients after high-dose 
rifaximin, and of these, 8%, 13%, and 18% of patients with 
diarrhea-  predominant IBS, constipation-predominant IBS, 
and mixed-symptom IBS, respectively, reported partial relief. 
In contrast with initial rifaximin therapy, high-dose rifaximin 
successfully normalized lactulose breath test results in nine 
of 81 patients (11%).
Adverse events
Of the 162 patients receiving initial rifaximin 1200 mg/day 
for 10 days, only 13 (8%) reported adverse events.   Similarly, 
only five of 81 patients (6%) administered additional Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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  rifaximin 2400 mg/day for 10 days reported adverse events. 
Most of these adverse events occurred in the first 3–4 days 
of treatment and consisted of flu-like illness with diarrhea 
and nausea. These symptoms resolved by day 5 and were 
thought to be secondary to “bacterial kill”.
Discussion
This retrospective chart review demonstrated that rifaximin 
1200 mg/day for 10 days improved global and IBS-related 
symptoms. This finding is consistent with data from two Phase 
III clinical trials showing that rifaximin 550 mg three times 
daily for 14 days adequately relieved global IBS symptoms 
and IBS-related bloating for at least two of the first four weeks 
of treatment, and improved daily assessments of IBS symp-
toms, bloating, abdominal pain, and stool consistency com-
pared with placebo.19 However, the initial dose of rifaximin 
examined in the current work (ie, rifaximin 1200 mg/day) 
was lower than that used in the Phase III trials (ie, 1650 mg/
day). Several prospective   studies have shown that rifaximin 
800 mg/day or 1200 mg/day for 10 days improved IBS symp-
toms and eradicated small intestinal bacterial overgrowth,15,16 
but because of differences in study design and inclusion 
criteria, it is not possible to compare these studies with the 
Phase III trials. Thus, the optimum dose of rifaximin for IBS 
remains unknown. Results from the current study, however, 
imply that patients who are initially unresponsive to rifaximin 
therapy may benefit from an escalation in rifaximin dose.
Few studies have examined the efficacy of rifaximin for 
specific subpopulations of IBS (ie, diarrhea-predominant 
IBS, constipation-predominant IBS, and mixed-symptom 
IBS). Phase III clinical trials of rifaximin have limited 
patient inclusion to “non-constipation IBS” (ie, diarrhea-
predominant IBS or mixed-symptom IBS);19 therefore, pos-
sible differences in the efficacy of rifaximin among patients 
with different IBS subtypes remains unknown. In the current 
study, rifaximin was effective in all subtypes of IBS. Although 
a greater percentage of patients with diarrhea-predominant 
IBS had an initial response, patients with mixed-symptom 
IBS were more likely to respond to high-dose rifaximin. In 
addition, symptoms of diarrhea and constipation were equally 
relieved in patients with mixed-symptom IBS.
Rifaximin is a generally well-tolerated nonsystemic 
antibiotic that elicits few adverse events. Studies of rifaximin 
800 mg/day or 1200 mg/day in patients with IBS demon-
strated a similar occurrence of adverse events in the placebo 
and rifaximin groups.5,15,16 Although one might expect a larger 
number of adverse events with an increased medication dose, 
rifaximin 1600 mg/day19 or 2400 mg/day is well tolerated.
These results are limited by the retrospective nature of the 
study and the lack of a placebo comparison group, but they 
provide evidence that rifaximin 1200 mg/day may be a safe 
and beneficial alterative for patients with IBS and that stud-
ies designed to examine the efficacy of rifaximin in patients 
with diverse IBS symptoms are warranted. Furthermore, 
higher doses of rifaximin (ie, 2400 mg/day) may increase 
the percentage of responsive patients.
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